



James L. Gulley, MD, PhD
SU2C Scientific Advisory Committee



James L. Gulley, MD, PhD

Chief of Genitourinary Malignancies Branch
Head of Immunotherapy Section at National Cancer Institute
Member, Stand Up To Cancer Scientific Advisory Committee
Bethesda, MD

James L. Gulley is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. Since 1998 he has authored and run a variety of clinical trials at the National Cancer Institute (NCI). These innovative, investigator-initiated studies involve the use of cancer immunotherapy to initiate immune responses, expand immune responses and/or allow the immune responses to be effective within the tumor microenvironment.

In addition to his role as Branch Chief, Dr. James L. Gulley is also Director of the Medical Oncology Service and Deputy Director of the Center for Cancer Research at the NCI. His areas of expertise include immunotherapy, therapeutic cancer vaccines, immune checkpoint inhibitors, prostate cancer, clinical trials, combining immunotherapy with other therapies

Dr. Gulley serves on many national and NIH boards and committees as well as the board of Loma Linda University Health. He has been an investigator on around 200 clinical trials, authored 350 scientific papers or chapters which have been cited around 20,000 times, serves on a number of editorial boards and has made hundreds of scientific presentations at universities or national / international meetings.

He has had multiple awards including the 2010 Presidential Early Career Award for Scientists and Engineers, the highest award bestowed by the US President on investigators early in their careers.

Dr. James Gulley graduated from Loma Linda University in California with a PhD in microbiology in 1994 and an MD in 1995. As part of this eight-year MD/PhD Medical Scientist Training Program, he completed a dissertation on tumor immunology. He completed his residency in Internal Medicine at Emory University in 1998, followed by a Medical Oncology fellowship at the National Cancer Institute.